Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:clinical_trial |
Phase 1 trials
|
| gptkbp:focuses_on |
RNA delivery technology
|
| gptkbp:founded |
gptkb:2018
|
| gptkbp:headquarters |
gptkb:Vancouver,_Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
Genevant Sciences
|
| gptkbp:key_people |
CEO, Dr. J. Michael Bishop
|
| gptkbp:partnerships |
gptkb:Roche
|
| gptkbp:products |
RNA-based therapeutics
|
| gptkbp:technology |
lipid nanoparticle delivery system
|
| gptkbp:website |
www.genevant.com
|
| gptkbp:bfsParent |
gptkb:Catalent
|
| gptkbp:bfsLayer |
5
|